Cytel Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Cambridge MA United States (1987)

Organization Overview

First Clinical Trial
2016
NCT02960893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cytel Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Iron-Deficiency (Phase 4)

Ataxia (Phase 3)

Cerebellar Ataxia (Phase 3)

Communicable Diseases (Phase 3)

Coronavirus Infections (Phase 3)

Heart Failure (Phase 4)

Infections (Phase 3)

Respiratory Tract Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Spinocerebellar Ataxias (Phase 3)

Spinocerebellar Degenerations (Phase 3)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 12